Areas of Focus
Advaxis’ Lm Technology™ is a versatile platform that alters the tumor microenvironment by increasing tumor-fighting cells and decreasing tumor protecting cells. Advaxis is maximizing the potential of its Lm Technology in three separate areas of focus.
Advaxis is validating its Lm Technology platform by evaluating the clinical safety and efficacy of its three investigational immunotherapies: axalimogene filolisbac (AXAL) in HPV-associated cancers, ADXS-PSA in prostate cancer and ADXS-HER2 in HER2-expressing solid tumors, including osteosarcoma, some breast cancers, esophageal and gastric cancer.
Advaxis’ Lm Technology is uniquely positioned to take advantage of recent advances in genome sequencing with the capacity potentially to target all of a patient’s immunogenic cancer neoepitopes, eliminating the need to use “predictive algorithms.” Advaxis’ MINE™ program uses its proprietary vector, ADXS-NEO, to trigger an immune response specific to each individual patient’s tumor. This technology may enable the development of truly individualized immunotherapies that can be manufactured in a cost-effective and timely manner. Advaxis is currently collaborating with Amgen to advance this program and is expected to begin clinical trials in 2017.
Advaxis’ global partnering strategy is to leverage the versatility of its Lm Technology platform and partner with other biopharmaceutical industry leaders and recognized cancer centers of excellence.